placeholder newsslider

News in Detail

Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Treatment Roclanda

Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.